GlassScriptPhysician profile
Tyler Kabes
NPI 1720433881
$9,512.18
in general payments reported to CMS, 2019-2025
22 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.86 · 2020: $4,087 · 2021: $219 · 2022: $1,699 · 2023: $1,074 · 2024: $1,812 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468 · Travel and Lodging: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.03 |
| Travel and Lodging | $977.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,408.85 | 2019-2024 | Proclaim |
| Boston Scientific Corporation | $1,834.53 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Medtronic USA, INC. | $1,575.00 | 2020 | |
| Nevro Corp. | $696.67 | 2020-2024 | Senza |
| Painteq LLC | $623.87 | 2022-2023 | Painteq |
| Medtronic, INC. | $244.94 | 2021-2025 | Inceptiv, Vanta Adaptivestim, Intellis Adaptivestim |
| Spr Therapeutics, INC | $186.64 | 2023-2025 | Sprint Pns System |
| Si-Bone, INC. | $177.12 | 2024 | |
| Curonix LLC | $153.28 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $127.42 | 2022-2023 | Belbuca, Xtampza |
| Globus Medical, INC. | $79.30 | 2025 | Senza |
| Abbvie INC. | $79.22 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $78.31 | 2023-2024 | Xeomin |
| Forte Bio-Pharma LLC | $59.51 | 2023 | Prolate, Nalocet |
| Idorsia Pharmaceuticals US INC | $47.63 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $32.90 | 2023 | Levorphanol Tartrate |
| Azurity Pharmaceuticals, INC. | $21.50 | 2023 | Horizant |
| Averitas Pharma INC. | $21.28 | 2025 | Qutenza |
| Pfizer INC. | $19.53 | 2023 | |
| Nalu Medical, INC. | $18.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.98 | 2024 | Relistor |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Kabes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.